Table I.
Distribution and timing of severe acute respiratory syndrome coronavirus 2 polymerase chain reaction and coronavirus disease 2019 antibody test results in relation to dermatologic manifestations
| Testing characteristic | Chilblains/pernio |
Nonchilblains/pernio |
All dermatologic conditions, including pernio and nonpernio |
||||||
|---|---|---|---|---|---|---|---|---|---|
| No. of pernio patients | No. of pernio patients with timing data | Pernio onset to testing interval, median (IQR), days | No. of nonpernio patients | No. of nonpernio patients with timing data | Nonpernio dermatologic symptom onset to testing interval, median (IQR), days | No. of patients | No. of patients with timing data | Dermatologic symptom onset to testing interval, median (IQR), days | |
| PCR testing | |||||||||
| PCR+ | 23 | 5 | 8 (5–14) | 185 | 62 | 6 (1–15) | 208 | 67 | 6 (1–14) |
| PCR– | 134 | 58 | 14 (7–28) | 27 | 10 | 9 (5–13) | 161 | 68 | 14 (7–24) |
| SARS-CoV-2–positive antibody testing | |||||||||
| IgM+/IgG+ | — | — | — | 1 | 1 | 14 | 1 | 1 | 14 |
| IgM+/IgG– | 7 | 7 | 24 (23–28) | — | — | — | 7 | 7 | 24 (23–28) |
| IgM–/IgG+ | 1 | 1 | 99 | 5 | 5 | 31 (14–32) | 6 | 6 | 32 (14–35) |
| IgM unknown/IgG+ | 3 | 3 | 35 (25–40) | 10 | 7 | 38 (14–46) | 12 | 10 | 37 (25–40) |
| Ig+ (isotype unknown) | 1 | 1 | 10 | 3 | 3 | 60 (30–107) | 5 | 4 | 45 (20–84) |
| SARS-CoV-2–negative antibody testing | |||||||||
| IgM–/IgG– | 17 | 5 | 37 (21–42) | 1 | — | — | 18 | 5 | 37 (21–42) |
| IgM unknown/IgG– | 35 | 16 | 38 (33–50) | 2 | 2 | 14 (0–27) | 37 | 18 | 36 (28–49) |
| Ig- (isotype unknown) | 11 | 6 | 34 (21–60) | — | — | — | 11 | 6 | 34 (21–60) |
IgM, Immunoglobulin M; IQR, interquartile range; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; +, positive; –, negative; —, no cases reported.